Austin Neuromuscular Center | Austin, TX
Status and phase
Conditions
Treatments
About
This trial is an extension of the antecedent trial ARGX-117-2002. It is a multicenter trial that has been designed to evaluate the long-term safety and tolerability, efficacy, immunogenicity, Pharmacokinetics (PK), and Pharmacodynamics (PD) of ARGX-117 Intravenously (IV) in adults with Multifocal Motor Neuropathy (MMN). The trial will include a double-blinded rollover treatment period (DTP), an open-label treatment period (OTP), and a safety follow-up period.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Capable of providing signed informed consent and complying with protocol requirements. Participants must be able to read and write.
Must have completed the double-blinded treatment period of the ARGX-117-2002 trial and considered to be eligible for treatment with ARGX-117
Agrees to use contraceptive measures consistent with local regulations and the following:
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
48 participants in 2 patient groups
Loading...
Central trial contact
Sabine Coppieters, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal